# EDGAR Filing Document

**Accession Number:** 0001949257
**File Stem:** 0000000000-23-003299
**Filing Date:** 2023-3
**Character Count:** 11463
**Document Hash:** 6517d2105d1c32eed48ceab14067bfc8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-003299.hdr.sgml**: 20241227

**ACCESSION NUMBER**: 0000000000-23-003299

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230331

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Radiopharm Theranostics Ltd
- **CENTRAL INDEX KEY:** 0001949257
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-06505

**BUSINESS ADDRESS:**
- **STREET 1:** LEVEL 3, 62 LYGON STREET
- **CITY:** CARLTON VIC
- **STATE:** C3
- **ZIP:** 3053
- **BUSINESS PHONE:** 61 3 9824 5254

**MAIL ADDRESS:**
- **STREET 1:** LEVEL 3, 62 LYGON STREET
- **CITY:** CARLTON VIC
- **STATE:** C3
- **ZIP:** 3053
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001213900-22-080267

## Text-Extract

```

United States securities and exchange commission logo

                             March 31, 2023

       Riccardo Canevari
       Chief Executive Officer
       Radiopharm Theranostics Ltd
       Level 3, 62 Lygon Street, Carlton VIC 3053
       Australia

                                                        Re: Radiopharm
Theranostics Ltd
                                                            Amendment No. 1 to
Registration Statement on Form 20FR12B
                                                            Filed March 20,
2023
                                                            File No. 001-41621

       Dear Riccardo Canevari:

              We have reviewed your filing and have the following comments. In
some of our
       comments, we may ask you to provide us with information so we may better
understand your
       disclosure.

              Please respond to these comments within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comments apply to your facts and circumstances, please tell us why in
your response.

            After reviewing your response and any amendment you may file in
response to these
       comments, we may have additional comments.

       Amendment No. 1 to Registration Statement on Form 20FR12B

       RAD Clinical Development Pipeline, page 26

   1.                                                   We note your response
to prior comment two. Your pipeline table should include material
                                                        product candidates in
development. Given your lack of current plans to develop RAD201,
                                                        it does not appear that
it is appropriate to continue to include this product candidate in
                                                        your pipeline table.
The facts that development could be resumed and the results of your
                                                        Phase I trials
supported your decision to pursue another candidate trial, which is depicted
                                                        in the table, is not
sufficient to continue to continue to include RAD201 in your pipeline
                                                        table.
       Stock Purchase Agreement with Pharma15 and its selling stockholders,
page 70

   2.                                                   We note your disclosure
regarding your recent acquisition of Pharma15 via a stock
                                                        purchase agreement, the
terms of which provide for post-closing contingent consideration
 Riccardo Canevari
Radiopharm Theranostics Ltd
March 31, 2023
Page 2
       of $3.2 million to Pharma15 selling stockholders which could be
satisfied by the issuance
       of Radiopharm ordinary shares depending on the price of such shares at
the time a grant
       occurs. Given your statement that you can issue up to 47,000,000
ordinary shares without
       shareholder approval to satisfy the contingent consideration under ASX
listing rules, and
       that this number of shares appears to be material relative to the number
of ordinary shares
       currently issued and outstanding, please include risk factor disclosure
addressing dilution
       your shareholders may experience and the potential impact such
additional issuance may
       have on the market price of your ordinary shares.
Sublicense Agreement with NeoIndicate, page 70

3.     Please disclose your obligation to pay an annual license maintenance fee
and quantify the
       amount of the fee.
Jurisdiction and Arbitration, page 89

4.     We note your revisions in response to prior comment 9, which we reissue.
You now state
       both on page 89 and in your risk factor on page 20 that the arbitration
provisions of the
       Deposit Agreement do not preclude ADS holders from pursuing claims under
the
       Securities Act or the Exchange Act    in federal courts," mirroring the
third paragraph of
       Section 7.6 in the Deposit Agreement. However, the fourth paragraph of
Section 7.6
       states that ADS holders irrevocably agree that any legal suit, action or
proceeding against
       or involving the Company or the Depositary may be instituted in a state
or federal court in
       New York, New York. Please revise exhibit 2.1 to eliminate this internal
inconsistency by
       stating that the arbitration provisions will not preclude ADS holders
from pursuing
       Securities Act or Exchange Act claims in state or federal courts, and
make conforming
       changes to your prospectus disclsoure. In this regard, we note that
Section 22 of the
       Securities Act creates concurrent jurisdiction for federal and state
courts over all suits
       brought to enforce any duty or liability created by the Securities Act
or the rules and
       regulations thereunder.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff. You may contact Gary Newberry at 202-551-3761 or Kevin
Kuhar at 202-
551-3662 if you have questions regarding comments on the financial statements
and related
matters. Please contact Lauren Hamill at 303-844-1008 or Suzanne Hayes at
202-551-3675 with
any other questions.

                                                            Sincerely,
FirstName LastNameRiccardo Canevari
Comapany NameRadiopharm Theranostics Ltd                    Division of
Corporation Finance
                                                            Office of Life
Sciences
March 31, 2023 Page 2
cc:
FirstName Alberto Pacchioni
          LastName

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

CORPORATION FINANCE

# UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 31, 2023

Riccardo Canevari  
Chief Executive Officer  
Radiopharm Theranostics Ltd  
Level 3, 62 Lygon Street, Carlton VIC 3053  
Australia

# **Re: Radiopharm Theranostics Ltd**

# **Amendment No. 1 to Registration Statement on Form 20FR12B**

**Filed March 20, 2023**

**File No. 001-41621**

Dear Riccardo Canevari:

We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to these comments within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response.

After reviewing your response and any amendment you may file in response to these comments, we may have additional comments.

# Amendment No. 1 to Registration Statement on Form 20FR12B

# RAD Clinical Development Pipeline, page 26

1. We note your response to prior comment two. Your pipeline table should include material product candidates in development. Given your lack of current plans to develop RAD201, it does not appear that it is appropriate to continue to include this product candidate in your pipeline table. The facts that development could be resumed and the results of your Phase I trials supported your decision to pursue another candidate trial, which is depicted in the table, is not sufficient to continue to include RAD201 in your pipeline table.

# Stock Purchase Agreement with Pharma15 and its selling stockholders, page 70

2. We note your disclosure regarding your recent acquisition of Pharma15 via a stock purchase agreement, the terms of which provide for post-closing contingent consideration

Riccardo Canevari  
Radiopharm Theranostics Ltd  
March 31, 2023  
Page 2

of $3.2 million to Pharma15 selling stockholders which could be satisfied by the issuance of Radiopharm ordinary shares depending on the price of such shares at the time a grant occurs. Given your statement that you can issue up to 47,000,000 ordinary shares without shareholder approval to satisfy the contingent consideration under ASX listing rules, and that this number of shares appears to be material relative to the number of ordinary shares currently issued and outstanding, please include risk factor disclosure addressing dilution your shareholders may experience and the potential impact such additional issuance may have on the market price of your ordinary shares.

# Sublicense Agreement with NeoIndicate, page 70

3. Please disclose your obligation to pay an annual license maintenance fee and quantify the amount of the fee.

# Jurisdiction and Arbitration, page 89

4. We note your revisions in response to prior comment 9, which we reissue. You now state both on page 89 and in your risk factor on page 20 that the arbitration provisions of the Deposit Agreement do not preclude ADS holders from pursuing claims under the Securities Act or the Exchange Act 'in federal courts,' mirroring the third paragraph of Section 7.6 in the Deposit Agreement. However, the fourth paragraph of Section 7.6 states that ADS holders irrevocably agree that any legal suit, action or proceeding against or involving the Company or the Depositary may be instituted in a state or federal court in New York, New York. Please revise exhibit 2.1 to eliminate this internal inconsistency by stating that the arbitration provisions will not preclude ADS holders from pursuing Securities Act or Exchange Act claims in state or federal courts, and make conforming changes to your prospectus disclosure. In this regard, we note that Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. You may contact Gary Newberry at 202-551-3761 or Kevin Kuhar at 202-551-3662 if you have questions regarding comments on the financial statements and related matters. Please contact Lauren Hamill at 303-844-1008 or Suzanne Hayes at 202-551-3675 with any other questions.

Sincerely,

Division of Corporation Finance

cc: Alberto Pacchioni